ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
Exploring the Relationship Between Daratumumab Treatment and Stem Cell Collection in Newly Diagnosed Multiple Myeloma (NDMM) Patients Undergoing Transplantation: Insights From a Single-Center Investigation.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Daratumumab-induction regimen has benefitted the multiple myeloma patients with long-lasting effective response. However, studies have showed daratumumab induction therapy reduced CD34+ stem cell yield and increased dependence on plerixafor use during mobilization therapy for subsequent autologous stem cell transplantation (ASCT). Here, we aim to explore the influence of daratumumab-based induction therapy on CD34+ stem cell yield in Indian multiple myeloma patients. Methods: In this retrospective study, electronic medical records of transplant eligible multiple myeloma patients ( Results: Among the 91 patients, 8 received daratumumab induction regimen. The CD34+ stem cell yield among daratumumab and non-daratumumab induction groups did not show significant difference (5.29 ± 1.64 × 10 Conclusion: The addition of daratumumab in induction therapy of multiple myeloma did not affect stem cell yield but increased dependence on plerixafor during mobilization therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.